| 3.9 -0.68 (-14.85%) | 06-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.8  |
1-year : | 8.6 |
| Resists | First : | 5.82 |
Second : | 7.36 |
| Pivot price | 5.51 |
|||
| Supports | First : | 3.32 |
Second : | 2.77 |
| MAs | MA(5) : | 4.57 |
MA(20) : | 5.8 |
| MA(100) : | 5.62 |
MA(250) : | 3.36  |
|
| MACD | MACD : | -0.6 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 10.8 |
D(3) : | 6.5 |
| RSI | RSI(14): 19.3 |
|||
| 52-week | High : | 8.32 | Low : | 0.71 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ STTK ] has closed below the lower bollinger band by 7.4%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 83.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.03 - 5.06 | 5.06 - 5.09 |
| Low: | 3.28 - 3.3 | 3.3 - 3.32 |
| Close: | 3.85 - 3.9 | 3.9 - 3.94 |
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Mon, 08 Jun 2026
Shattuck Labs Put Its Lead Drug Candidate Center Stage - Finimize
Mon, 08 Jun 2026
Why Is Shattuck Labs Stock Trading Lower On Monday? - Benzinga
Mon, 08 Jun 2026
Shattuck Labs announces positive Phase 1 results for SL-325 - grafa.com
Mon, 08 Jun 2026
Shattuck Labs (STTK) Reports Positive Phase 1 Trial Outcomes for SL-325 - GuruFocus
Mon, 08 Jun 2026
Shattuck Labs stock jumps 17% on Phase 1 trial results - Investing.com
Mon, 08 Jun 2026
Shattuck Labs Announces Phase 1 Results for SL-325 - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 77 (M) |
| Held by Insiders | 4.783e+007 (%) |
| Held by Institutions | 5.2 (%) |
| Shares Short | 1,340 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.894e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 258.2 % |
| Return on Equity (ttm) | -36.7 % |
| Qtrly Rev. Growth | 1e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -51.3 |
| EBITDA (p.s.) | -2.5042e+006 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -41 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.08 |
| Price to Cash Flow | 3.57 |
| Dividend | 0 |
| Forward Dividend | 1.32e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|